KITE - TCR THERAPY
TCR therapy is a type of cellular immunotherapy designed to redirect the patient’s immune system in order to recognize and target tumors.
KITE - TCR THERAPY
Industry:
Pharmaceutical
Address:
Los Angeles, California, United States
Country:
United States
Status:
Active
More informations about "Kite - TCR therapy"
Kite - TCR therapy - Crunchbase Company Profile & Funding
Jul 19, 2021 Kite - TCR therapy is a type of cellular immunotherapy designed to redirect the patient’s immune system. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. …See details»
Kite Pharma, Changing the Way Cancer is Treated
If you’re passionate about advancing the next generation of cell therapy treatment, find your career at Kite. Find Your Career . Kite News Newsroom. Recent Press Releases. December …See details»
BioNTech Completes Acquisition of Kite’s Neoantigen TCR Cell …
Aug 4, 2021 The acquisition strengthens BioNTech’s cell therapy pipeline by accelerating the individualized solid tumor Neoantigen TCR cell therapy research and development program. It …See details»
BioNTech grows in cell therapies, buying Kite's TCR …
Dec 11, 2024 Kite's most advanced TCR therapy is KITE-439, for solid tumours associated with human papillomavirus (HPV) type 16, including cervical, head and neck, anal and genital cancers.See details»
BioNTech to Acquire Kite’s Neoantigen TCR Cell Therapy R&D …
Jul 19, 2021 Kite’s neoantigen TCR platform enables the development of individualized TCR therapies that are custom designed to target individual neoantigens on a patient’s tumor. This …See details»
BioNTech returns to cancer roots with deal for Gilead cell therapy ...
Jul 19, 2021 The German biotech purchased Kite Pharma's Gaithersburg, Maryland-based site, along with related research on T cell receptor-based cancer treatments. ... TCR therapy, like …See details»
BioNTech to Acquire Kite’s TCR Platform for Cell Therapy Pipeline
Jul 21, 2021 TCR therapy is a type of cellular immunotherapy designed to redirect the patient’s immune system to recognize and target tumors, a Gilead spokesperson explained. ... Kite’s …See details»
Kite Pharma - Crunchbase Company Profile & Funding
Kite Pharma is a development-stage biotechnology company designing and developing immune-based therapies to treat cancer indications. ... 169 Number of Organizations • $46.3B Total Funding Amount • 459 Number of Investors. ...See details»
BioNTech to Acquire Kite’s TCR Cell Therapy Platform and …
Jul 21, 2021 BioNTech and Kite, a Gilead company, announced on July 19, 2021 that they have entered into a purchase agreement for BioNTech to acquire Kite’s solid tumor neoantigen T …See details»
BioNTech Buys Kite TCR Cell Therapy Plant - PharmaLive
Jul 19, 2021 Germany’s BioNTech announced it is acquiring Kite’s solid tumor neoantigen T-cell receptor (TCR) research-and-development platform and its clinical manufacturing plant in …See details»
Kite Announces Initial Results From a Phase 1 Study of T Cell …
TCR therapy candidates for a variety of cancers in partnership with the NCI. KITE-439 is investigational and has not been proven safe or efficacious. About Kite Kite, a Gilead …See details»
Kite adds to T-cell receptor platform with HiFiBiO deal
Oct 3, 2018 Since then, Kite has advanced its lead TCR candidates into clinical trials, including KITE-439 for HPV-associated solid tumors—which has initial phase 1 results and also grew …See details»
BioNTech selects Maryland for U.S. manufacturing facility
Jul 27, 2021 BioNTech is acquiring a Gaithersburg manufacturing facility and cell therapy R&D platform from Kite, a unit of Gilead Sciences, to support the development of BioNTech’s …See details»
Kite Pharma Strengthens Its T Cell Receptor (TCR) Cancer Gene …
SANTA MONICA, Calif., March 17, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing …See details»
Kite Pharma Uses CRADAs to Conduct Important Clinical Research …
Oct 19, 2016 Kite Pharma, Inc., which is racing Juno Therapeutics and Swiss pharmaceutical giant Novartis to successfully bring the first T-cell receptor (TCR) therapy to market, relies …See details»
Kite Pharma: How High Will It Fly? - Seeking Alpha
Jun 12, 2017 Engineered T cells therapy is showing highly promising early trials results as the next potential cancer breakthrough. ... In addition, lead TCR product candidate (KITE-718) is …See details»
KITE-718 - Drug Targets, Indications, Patents - Synapse
The JV at the time had the option to license additional Kite candidates, including TCR therapies KITE-439 and KITE-718, both of which have since been discontinued at Kite.Now, Fosun said …See details»
Therapy Group in Woodbridge & Manassas, VA - Woodbridge …
Woodbridge Therapy Group in Woodbridge, VA & Prince William Family Counseling in Manassas, VA, provide various therapy services. Make an appointment now. Call Woodbridge Therapy …See details»
Autism Behavior Therapies LLC - Woodbridge Office | ABA …
Our mission at Autism Behavior Therapies is to foster growth and positive behavior change. Applied Behavior Analysis (ABA) is the leading, research-based methodology for bringing …See details»
ABA THERAPY AT FREDERICKSBURG, VIRGINIA, Speech therapy in …
Dr. Arora started Sensational Kidz Therapy (providing center-based OT, PT, Speech Therapy and nutritional services) in 2008 and Behavior Innovations (providing home and center-based ABA …See details»